
  
    
      
        
        The_DT term_NN “ parasite_NN” derives_VBZ from_IN a_DT classical_JJ Greek_JJ word_NN that_WDT was_VBD used_VBN to_TO refer_VB to_TO “ a_DT
        guest_NN who_WP comes_VBZ to_TO dinner_NN and_CC does_VBZ n't_RB leave_VB” or_CC “ a_DT class_NN of_IN priests_NNS who_WP had_VBD meals_NNS at_IN public_JJ
        expense_NN” (_( Clitodemus_NNP ,_, in_IN 
        Athenaeus_NNP Grammaticus_NNP ,_, ca_MD ._. 378_CD B_NNP ._. C_NNP ._. )_) ._. In_IN modern_JJ usage_NN ,_, it_PRP
        refers_VBZ to_TO eukaryotic_JJ organisms_NNS that_WDT range_NN from_IN single-cell_JJ protozoa_NN to_TO complex_JJ
        multicellular_NN worms_NNS ._. The_DT diseases_NNS caused_VBN by_IN these_DT organisms_NNS represent_VBP some_DT of_IN the_DT world_NN 's_POS
        greatest_JJS health_NN problems_NNS ._.
        Malaria_NNP ,_, for_IN example_NN ,_, currently_RB affects_VBZ about_RB 500_CD million_CD people_NNS and_CC causes_NNS about_IN 3_CD ,_, 000_CD
        deaths_NNS a_DT day—mostly_RB in_IN sub-_NN Saharan_NNP Africa_NNP [_NN 1_CD ]_NN ._. Schistosomiasis_NNP ,_, caused_VBN by_IN 
        Schistosoma_NNP spp_NN ._. (_( blood_NN flukes_NNS )_) ,_, affects_VBZ over_IN 250_CD million_CD people_NNS
        in_IN the_DT tropical_JJ world_NN [_NN 2_CD ]_NN ,_, and_CC a_DT recent_JJ meta-analysis_JJ showed_VBD that_IN the_DT disease_NN is_VBZ
        significantly_RB associated_VBN with_IN anemia_NN ,_, chronic_JJ pain_NN ,_, diarrhea_NN ,_, exercise_NN intolerance_NN ,_, and_CC
        undernutrition_NN [_NN 3_CD ]_NN ._. Almost_RB a_DT billion_CD people_NNS are_VBP infected_VBN with_IN the_DT nematode_NN parasites_NNS :_: 
        Ascaris_NNP (_( roundworm_NN )_) ,_, 
        Ancylostoma_NNP (_( hookworm_NN )_) ,_, and_CC 
        Trichuris_NNP (_( whipworm_NN )_) [_NN 2_CD ]_NN ._. Why_WRB then_RB have_VBP so_RB few_JJ effective_JJ drugs_NNS
        been_VBN produced_VBN against_IN these_DT diseases_NNS ?_.
        The_DT answer_NN lies_VBZ primarily_RB in_IN the_DT fact_NN that_IN these_DT are_VBP diseases_NNS affecting_VBG people_NNS who_WP are_VBP
        poor_JJ and_CC living_VBG in_IN poor_JJ regions_NNS of_IN the_DT world_NN ._. They_PRP represent_VBP little_JJ or_CC no_DT viable_JJ market_NN for_IN
        the_DT pharmaceutical_JJ industry_NN ,_, especially_RB given_VBN the_DT market_NN requirements_NNS of_IN the_DT recently_RB
        merged_VBN pharmaceutical_JJ giants_NNS ._. Given_VBN this_DT reality_NN ,_, how_WRB can_MD imaginative_JJ and_CC effective_JJ
        strategies_NNS be_VB developed_VBN to_TO meet_VB this_DT challenge_NN ?_.
      
      
        New_JJ Strategies_NNS for_IN Antiparasitic_NNP Drug_NNP Design_NNP
        At_IN last_JJ year_NN 's_POS meeting_NN of_IN the_DT American_NNP Society_NNP of_IN Tropical_NNP Medicine_NNP and_CC Hygiene_NNP ,_, the_DT
        organization_NN that_IN hosts_NNS one_CD of_IN the_DT largest_JJS international_JJ gatherings_NNS of_IN basic_JJ scientists_NNS and_CC
        tropical_JJ medicine_NN specialists_NNS ,_, several_JJ symposia_NN highlighted_VBD efforts_NNS in_IN antiparasitic_JJ drug_NN
        design_NN ._. What_WP was_VBD five_CD years_NNS ago_RB a_DT fairly_RB dark_JJ vision_NN of_IN the_DT future_NN ,_, now_RB appears_VBZ
        brighter_JJR ._.
        Several_JJ nonprofit_JJ organizations_NNS are_VBP now_RB operating_VBG that_WDT are_VBP dedicated_VBN to_TO this_DT unmet_JJ
        medical_JJ need_VBP ,_, some_DT collaborative_JJ interest_NN exists_VBZ in_IN industry_NN ,_, and_CC philanthropies_NNS have_VBP
        backed_VBN new_JJ initiatives_NNS ._. There_EX are_VBP also_RB a_DT number_NN of_IN new_JJ academic_JJ consortia_NN with_IN novel_NN
        strategies_NNS to_TO address_VB issues_NNS of_IN target_NN discovery_NN and_CC preclinical_JJ development_NN ._.
        
        Strategy_NN one_CD :_: Developing_VBG a_DT drug_NN that_WDT has_VBZ both_DT a_DT commercial_JJ market_NN in_IN the_DT west_NN
        and_CC an_DT application_NN against_IN a_DT neglected_VBN parasitic_JJ disease_NN ._. This_DT strategy_NN is_VBZ exemplified_VBN
        by_IN the_DT international_JJ consortium_NN of_IN researchers_NNS organized_VBN by_IN Dr_NNP ._. Richard_NNP Tidwell_NNP of_IN the_DT
        University_NNP of_IN North_NNP Carolina_NNP ._. With_IN funding_NN from_IN the_DT Bill_NNP and_CC Melinda_NNP Gates_NNP Foundation_NNP ,_, more_JJR
        than_IN a_DT dozen_NN faculty_NN and_CC scientists_NNS from_IN six_CD research_NN institutions_NNS (_( see_VB Box_NNP 1_LS )_) are_VBP working_VBG
        in_IN collaboration_NN with_IN Immtech_NNP International_NNP to_TO manage_VB the_DT “ cross-over_JJ” development_NN of_IN
        antifungals_NNS produced_VBN by_IN Immtech_NNP as_IN potential_JJ drugs_NNS for_IN African_JJ trypanosomiasis_NNS ,_, also_RB known_VBN
        as_IN African_JJ sleeping_NN sickness_NN ._. This_DT approach_NN takes_VBZ advantage_NN of_IN drug_NN development_NN of_IN a_DT class_NN
        of_IN compounds_NNS targeting_VBG a_DT viable_JJ commercial_JJ market_NN for_IN Immtech_NNP (_( fungal_NN diseases_NNS of_IN the_DT
        developed_VBN world_NN )_) ._. At_IN the_DT same_JJ time_NN ,_, academic-_NN and_CC nonprofit-institute_JJ scientists_NNS are_VBP
        targeting_VBG these_DT compounds_NNS in_IN parallel_JJ toward_IN an_DT “ unprofitable_JJ” major_JJ health_NN problem—_NN African_JJ
        sleeping_NN sickness_NN ._. Specifically_RB ,_, an_DT analog_NN of_IN the_DT antifungal_NN pentamidine_NN has_VBZ been_VBN optimized_JJ
        as_IN a_DT trypanocidal_NN agent_NN and_CC is_VBZ in_IN clinical_JJ trials_NNS in_IN Africa_NNP ._.
        
        Strategy_NN two_CD :_: An_DT academic_JJ consortium_NN gets_VBZ federal_JJ support_NN for_IN pharmacokinetic_JJ
        and_CC toxicology_NN studies_NNS ._. This_DT second_JJ strategy_NN is_VBZ exemplified_VBN by_IN work_NN under_IN the_DT
        leadership_NN of_IN Dr_NNP ._. Donald_NNP Krogstad_NNP and_CC colleagues_NNS at_IN Tulane_NNP University_NNP ._. Here_RB ,_, without_IN an_DT
        industrial_JJ partner_NN ,_, Krogstad_NNP and_CC colleagues_NNS are_VBP using_VBG in-house_JJ chemistry_NN and_CC computational_NN
        assistance_NN to_TO modify_VB chloroquine_NN analogs_NNS in_IN an_DT effort_NN to_TO overcome_VB the_DT problem_NN of_IN
        chloroquine_NN resistance_NN in_IN malaria_NN treatment_NN ._. Their_PRP$ main_JJ partner_NN in_IN this_DT effort_NN is_VBZ the_DT
        National_NNP Institute_NNP of_IN Allergy_NNP and_CC Infectious_NNP Diseases_NNP ,_, which_WDT has_VBZ provided_VBN support_NN for_IN
        pharmacokinetic_JJ and_CC toxicology_NN studies_NNS by_IN virtue_NN of_IN pre-existing_JJ contracts_NNS with_IN SRI_NNP
        International_NNP (_( an_DT independent_NN nonprofit_JJ research-and-development_NN organization_NN )_) in_IN Menlo_NNP
        Park_NNP ,_, California_NNP ,_, United_NNP States_NNPS ._. At_IN least_JJS one_CD compound_NN from_IN this_DT series_NN is_VBZ entering_VBG
        clinical_JJ trials_NNS ._.
        
        Strategy_NN three_CD :_: An_DT academic_JJ center_NN uses_VBZ a_DT philanthropic_JJ gift_NN to_TO woo_VB expertise_NN
        from_IN industry_NN and_CC build_VB infrastructure_NN for_IN preclinical_JJ drug_NN development_NN ._. This_DT third_JJ
        strategy_NN is_VBZ represented_VBN by_IN the_DT center_NN that_IN I_PRP direct_JJ ,_, the_DT Sandler_NNP Center_NNP for_IN Basic_NNP Research_NNP
        in_IN Parasitic_NNP Diseases_NNP at_IN the_DT University_NNP of_IN California_NNP ,_, San_NNP Francisco_NNP (_( UCSF_NNP )_) ._. Here_RB ,_,
        philanthropic_JJ support_NN was_VBD used_VBN to_TO build_VB infrastructure_NN for_IN a_DT consortium_NN of_IN laboratories_NNS
        that_WDT mimics_VBZ what_WP might_MD be_VB found_VBN in_IN a_DT small-_NN to_TO medium-sized_JJ pharmaceutical_JJ company_NN
        organized_VBN to_TO carry_VB out_IN preclinical_JJ drug_NN discovery_NN and_CC development_NN ._. These_DT core_NN laboratories_NNS
        include_VBP computational_NN support_NN for_IN drug_NN discovery_NN and_CC chemical_NN library_NN selection_NN ,_, X-_NNP ray_NN
        crystallography_NN ,_, drug_NN metabolism_NN and_CC toxicology_NN facilities_NNS ,_, animal_NN models_NNS of_IN parasitic_JJ
        diseases_NNS ,_, high-throughput_JJ screening_NN ,_, and_CC synthetic_JJ chemistry_NN ._.
        Initial_JJ work_NN at_IN this_DT center_NN focused_VBN on_IN a_DT drug_NN lead_NN for_IN Chagas_NNP disease_NN and_CC was_VBD supported_VBN
        by_IN a_DT Tropical_NNP Disease_NNP Research_NNP Unit_NNP Program_NNP project_NN grant_NN from_IN the_DT National_NNP Institute_NNP of_IN
        Allergy_NNP and_CC Infectious_NNP Diseases_NNP ._. This_DT compound_NN ,_, now_RB a_DT drug_NN candidate_NN ,_, was_VBD originally_RB
        synthesized_JJ by_IN Dr_NNP ._. Jim_NNP Palmer_NNP of_IN Khepri_NNP Pharmaceuticals_NNP (_( now_RB Celera_NNP )_) as_IN part_NN of_IN an_DT industry_NN
        search_NN for_IN anti-inflammatory_JJ and_CC anticancer_NN drugs_NNS focusing_VBG on_IN cysteine_NN proteases_NNS ._.
        Validation_NNP of_IN this_DT compound_NN as_IN an_DT antiparasitic_JJ was_VBD carried_VBN out_IN by_IN the_DT UCSF_NNP team_NN through_IN
        rodent_NN models_NNS of_IN disease_NN and_CC ,_, next_JJ ,_, supported_VBN ,_, as_IN in_IN the_DT case_NN of_IN the_DT Tulane_NNP consortium_NN ,_, by_IN
        Dr_NNP ._. Chuck_NNP Litterst_NNP ,_, Director_NNP of_IN the_DT National_NNP Institute_NNP of_IN Allergy_NNP and_CC Infectious_NNP Diseases_NNP
        Drug_NNP Development_NNP and_CC Surveillance_NNP Group_NNP ._. The_DT UCSF_NNP group_NN initially_RB handed_VBD over_IN further_JJ
        development_NN of_IN a_DT drug_NN candidate_NN to_TO the_DT Institute_NNP for_IN OneWorld_NNP Health_NNP (_( iOWH_NN )_) ,_, one_CD of_IN the_DT
        nonprofit_JJ organizations_NNS that_WDT has_VBZ sprung_VBN up_RP to_TO meet_VB “ downstream_JJ” drug_NN development_NN needs_VBZ for_IN
        neglected_VBN diseases_NNS (_( see_VB Sidebar_NNP )_) ._. iOWH_NN facilitated_JJ tests_NNS of_IN drug_NN safety_NN ,_, minimum_JJ effective_JJ
        dose_NN ,_, and_CC a_DT formulation_NN for_IN large-scale_JJ Good_NNP Manufacturing_NNP Practice_NNP manufacture_VB ._. The_DT Drugs_NNS
        for_IN Neglected_NNP Diseases_NNP Initiative_NNP (_( www_NN ._. dndi_NN ._. org_NN )_) has_VBZ now_RB become_VBN the_DT main_JJ partner_NN for_IN
        further_JJ development_NN [_NN 4_CD ]_NN ._. The_DT Sandler_NNP Center_NNP consortium_NN itself_PRP is_VBZ now_RB focusing_VBG on_IN completing_VBG
        preclinical_JJ development_NN of_IN similar_JJ drug_NN candidates_NNS targeting_VBG homologous_RB enzymes_NNS in_IN several_JJ
        other_JJ major_JJ global_JJ pathogens_NNS ._.
        There_EX is_VBZ another_DT way_NN in_IN which_WDT this_DT third_JJ strategy_NN represents_VBZ a_DT radical_JJ departure_NN from_IN
        the_DT usual_JJ research_NN paradigm_NN of_IN academic_JJ centers_NNS ._. A_DT High-_NNP Throughput_NNP Screening_NNP Center_NNP has_VBZ
        been_VBN established_VBN by_IN the_DT Sandler_NNP Center_NNP consortium_NN ,_, building_NN upon_IN the_DT expertise_NN of_IN Drs_NNP ._. Kip_NNP
        Guy_NNP (_( now_RB director_NN of_IN the_DT center_NN )_) and_CC Janice_NNP Williams_NNP (_( now_RB manager_NN of_IN the_DT center_NN )_) ,_, who_WP
        brought_VBD an_DT industrial_JJ perspective_NN to_TO the_DT university_NN ._. A_DT recently_RB completed_VBN screen_NN used_VBD an_DT
        assay_NN that_WDT allowed_VBD robotic_JJ screening_NN of_IN a_DT library_NN of_IN thousands_NNS of_IN FDA-approved_JJ drugs_NNS and_CC
        natural_JJ products_NNS for_IN activity_NN against_IN 
        Trypanosoma_NNP brucei_NN ,_, the_DT parasite_NN that_WDT causes_NNS African_JJ sleeping_NN
        sickness_NN ._. The_DT “ hit_VBN list_NN” from_IN this_DT screen_NN is_VBZ being_VBG made_VBN available_JJ on_IN a_DT Web_NNP site_NN
        (_( http_NN :_: /_NN /_NN itsa_NN ._. ucsf_NN ._. edu_NN /_NN ~_NN schisto_NN /_NN fruit_NN ._. html_NN )_) for_IN those_DT organizations_NNS (_( such_JJ as_IN the_DT Drugs_NNS for_IN
        Neglected_NNP Diseases_NNP Initiative_NNP [_NN 4_CD ]_NN ,_, iOWH_NN ,_, and_CC the_DT World_NNP Health_NNP Organization_NNP )_) whose_WP$ missions_NNS
        include_VBP licensing_NN ,_, manufacture_VB ,_, and_CC distribution_NN ._. Similar_JJ screens_NNS are_VBP being_VBG set_VBN up_RP for_IN
        leishmaniasis_NNS ,_, Chagas_NNP disease_NN ,_, schistosomiasis_NNS ,_, and_CC malaria_NN ._.
      
      
        A_DT New_NNP Drug_NNP Pipeline_NNP
        The_DT success_NN of_IN these_DT three_CD unusual_JJ strategies_NNS ,_, all_DT originating_VBG within_IN academic_JJ centers_NNS ,_,
        provides_VBZ a_DT new_JJ drug_NN pipeline_NN for_IN parasitic_JJ diseases_NNS with_IN no_DT market_NN value_NN for_IN the_DT
        pharmaceutical_JJ industry_NN (_( Figure_NN 1_LS )_) ._. The_DT future_NN is_VBZ likely_JJ to_TO see_VB a_DT number_NN of_IN academic_NN or_CC
        academic–industrial_NN collaborations_NNS supporting_VBG preclinical_JJ development_NN in_IN consortia_NN like_IN
        those_DT described_VBN above_IN ._.
        This_DT prediction_NN was_VBD already_RB borne_VBN out_RB at_IN the_DT April_NNP 2005_CD meeting_NN ,_, “ Drug_NNP Development_NNP for_IN
        Diseases_NNP of_IN Protozoa_NNP ,_,” sponsored_VBN by_IN the_DT Keystone_NNP Symposia_NNP ._. In_IN the_DT short_JJ time_NN since_IN the_DT
        American_NNP Society_NNP of_IN Tropical_NNP Medicine_NNP and_CC Hygiene_NNP meeting_NN ,_, it_PRP has_VBZ become_VBN clear_JJ that_IN more_RBR
        academic_JJ laboratories_NNS are_VBP encouraged_VBN to_TO pursue_VB drug_NN discovery_NN and_CC development_NN avenues_NNS
        beyond_IN research_NN traditionally_RB thought_VBD of_IN as_IN academic_NN ._. New_JJ consortia_NN modeled_VBD after_IN the_DT three_CD
        described_VBD above_IN are_VBP now_RB functional_JJ or_CC in_IN late_JJ planning_NN stages_NNS at_IN the_DT University_NNP of_IN
        Washington_NNP ,_, Johns_NNP Hopkins_NNP University_NNP ,_, Harvard_NNP University_NNP ,_, and_CC the_DT University_NNP of_IN Dundee_NNP ._. In_IN
        addition_NN ,_, significant_JJ help_NN from_IN some_DT large_JJ pharmaceutical_JJ companies_NNS ,_, notably_RB the_DT Trés_NNP
        Cantos_NNP laboratory_NN of_IN GlaxoSmithKline_NNP ,_, has_VBZ fueled_VBN focused_VBN academic-_NN and_CC
        nonprofit-organization_JJ drug_NN development_NN efforts_NNS ._. Three_CD nonprofit_JJ organizations_NNS (_( the_DT Drugs_NNS
        for_IN Neglected_NNP Diseases_NNP Initiative_NNP ,_, iOWH_NN ,_, and_CC the_DT Medicines_NNP for_IN Malaria_NNP Venture_NNP )_) are_VBP
        actively_RB working_VBG to_TO support_VB various_JJ stages_NNS of_IN the_DT drug-development_JJ pipeline_NN ._. Their_PRP$ efforts_NNS
        are_VBP particularly_RB key_JJ to_TO the_DT “ downstream_JJ” elements_NNS of_IN drug_NN manufacture_NN and_CC clinical_JJ
        trials_NNS ._.
        Finally_RB ,_, philanthropic_JJ organizations_NNS such_JJ as_IN the_DT Bill_NNP and_CC Melinda_NNP Gates_NNP Foundation_NNP ,_, the_DT
        Sandler_NNP Family_NNP Supporting_VBG Foundation_NNP ,_, and_CC the_DT Ellison_NNP Foundation_NNP have_VBP contributed_VBN to_TO these_DT
        endeavors_NNS ._. Their_PRP$ continued_JJ support_NN ,_, and_CC the_DT recruitment_NN of_IN other_JJ interested_JJ parties_NNS ,_, will_MD
        be_VB crucial_JJ to_TO maintaining_VBG the_DT momentum_NN engendered_JJ by_IN the_DT three_CD projects_NNS outlined_VBN here_RB ._.
        
          Editorial_NNP Note_VB :_: PloS_NNP has_VBZ received_VBN financial_JJ support_NN in_IN the_DT form_NN of_IN a_DT grant_NN
          from_IN the_DT Sandler_NNP Family_NNP Supporting_VBG Foundation_NNP ._.
        
      
    
  
